Our 650 employees develop and manufacture
active ingredients and pharmaceuticals
to the highest international standards.

Since 2008, we have been a subsidiary of France’s
FAREVA Group, which operates in 13 countries and has 43 production sites and 15 research and development centers around the world.

We focus on developing and manufacturing products for cancer treatment and immunosuppressive therapies.